{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Melanoma&page=20",
    "query": {
      "condition": "Melanoma",
      "page": 20
    },
    "page_size": 10
  },
  "pagination": {
    "page": 20,
    "page_size": 10,
    "total_count": 2274,
    "total_pages": 228,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Melanoma&page=21&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Melanoma&page=19&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-24T06:25:03.128Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04879017",
      "title": "FHD-286 in Subjects With Metastatic Uveal Melanoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic Uveal Melanoma"
      ],
      "interventions": [
        {
          "name": "FHD-286",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Foghorn Therapeutics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 76,
      "start_date": "2021-05-11",
      "completion_date": "2023-11-30",
      "has_results": false,
      "last_update_posted_date": "2024-04-25",
      "last_synced_at": "2026-10-24T06:25:03.128Z",
      "location_count": 9,
      "location_summary": "Los Angeles, California • Miami, Florida • Boston, Massachusetts + 4 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04879017"
    },
    {
      "nct_id": "NCT04513028",
      "title": "Beta Glucan's Effect on Pembrolizumab Immunologic Response in Stage III-IV Melanoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Melanoma Stage III",
        "Melanoma Stage IV"
      ],
      "interventions": [
        {
          "name": "Beta-Glucan",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Kelly McMasters",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2020-11-03",
      "completion_date": "2027-01-15",
      "has_results": false,
      "last_update_posted_date": "2025-10-30",
      "last_synced_at": "2026-10-24T06:25:03.128Z",
      "location_count": 1,
      "location_summary": "Louisville, Kentucky",
      "locations": [
        {
          "city": "Louisville",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04513028"
    },
    {
      "nct_id": "NCT01978236",
      "title": "Dabrafenib/Trametinib, BRAF or BRAF AND MEK Pre-op With BRAF and MEK Post-op, Phase IIB, Melanoma With Brain Mets,Biomarkers and Metabolites",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Melanoma and Brain Metastases"
      ],
      "interventions": [
        {
          "name": "Dabrafenib 150 mg",
          "type": "DRUG"
        },
        {
          "name": "Trametinib 2.0 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 6,
      "start_date": "2014-04-08",
      "completion_date": "2017-04-26",
      "has_results": true,
      "last_update_posted_date": "2018-08-17",
      "last_synced_at": "2026-10-24T06:25:03.128Z",
      "location_count": 2,
      "location_summary": "Pittsburgh, Pennsylvania • Houston, Texas",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01978236"
    },
    {
      "nct_id": "NCT05060432",
      "title": "Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Cancer",
        "Lung Cancer",
        "Head and Neck Cancer",
        "Melanoma"
      ],
      "interventions": [
        {
          "name": "EOS-448",
          "type": "DRUG"
        },
        {
          "name": "pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "inupadenant",
          "type": "DRUG"
        },
        {
          "name": "Dostarlimab",
          "type": "DRUG"
        },
        {
          "name": "SOC chemotherapies",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "iTeos Belgium SA",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 153,
      "start_date": "2021-09-06",
      "completion_date": "2025-07",
      "has_results": false,
      "last_update_posted_date": "2024-06-21",
      "last_synced_at": "2026-10-24T06:25:03.128Z",
      "location_count": 2,
      "location_summary": "San Diego, California • Bergen, New Jersey",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Bergen",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05060432"
    },
    {
      "nct_id": "NCT03767348",
      "title": "Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer (NSCLC)",
        "Microsatellite Instability-High (MSI-H)",
        "Non-melanoma Skin Cancer (NMSC)",
        "Cutaneous Melanoma"
      ],
      "interventions": [
        {
          "name": "RP1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "nivolumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Replimune, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 340,
      "start_date": "2017-09-20",
      "completion_date": "2028-12",
      "has_results": false,
      "last_update_posted_date": "2026-02-13",
      "last_synced_at": "2026-10-24T06:25:03.128Z",
      "location_count": 26,
      "location_summary": "Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 21 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03767348"
    },
    {
      "nct_id": "NCT00110019",
      "title": "Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Mucosal Melanoma",
        "Recurrent Melanoma",
        "Stage IIIA Skin Melanoma",
        "Stage IIIB Skin Melanoma",
        "Stage IIIC Skin Melanoma",
        "Stage IV Skin Melanoma"
      ],
      "interventions": [
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "Sorafenib Tosylate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 823,
      "start_date": "2005-06",
      "completion_date": "2012-08",
      "has_results": true,
      "last_update_posted_date": "2015-10-19",
      "last_synced_at": "2026-10-24T06:25:03.128Z",
      "location_count": 218,
      "location_summary": "Birmingham, Alabama • Fort Smith, Arkansas • Little Rock, Arkansas + 175 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Fort Smith",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Burbank",
          "state": "California"
        },
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00110019"
    },
    {
      "nct_id": "NCT01196416",
      "title": "Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Combination With Cisplatin, Vinblastine, and Temozolomide in Treating Patients With Recurrent or Metastatic Melanoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Melanoma",
        "Stage IV Skin Melanoma"
      ],
      "interventions": [
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Gamma-Secretase Inhibitor RO4929097",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        },
        {
          "name": "Temozolomide",
          "type": "DRUG"
        },
        {
          "name": "Vinblastine Sulfate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 14,
      "start_date": "2010-08",
      "completion_date": "2015-08",
      "has_results": true,
      "last_update_posted_date": "2019-11-18",
      "last_synced_at": "2026-10-24T06:25:03.128Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01196416"
    },
    {
      "nct_id": "NCT01425008",
      "title": "Study of MLN2480 in Participants With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion in Participants With Metastatic Melanoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Melanoma",
        "Metastatic Melanoma",
        "Solid Tumor",
        "Neoplasm"
      ],
      "interventions": [
        {
          "name": "MLN2480",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Millennium Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 149,
      "start_date": "2011-09-15",
      "completion_date": "2018-10-16",
      "has_results": true,
      "last_update_posted_date": "2020-08-10",
      "last_synced_at": "2026-10-24T06:25:03.128Z",
      "location_count": 9,
      "location_summary": "San Francisco, California • Denver, Colorado • Augusta, Georgia + 6 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Augusta",
          "state": "Georgia"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01425008"
    },
    {
      "nct_id": "NCT02038218",
      "title": "Study of 4-Demethyl-4-cholesteryloxycarbonylpenclome (DM-CHOC-PEN) in Patients With Brain Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Primary Brain Tumors",
        "Metastatic Malignant Neoplasm to Brain"
      ],
      "interventions": [
        {
          "name": "4-Demethyl-4-cholestryloxycarbonylpenclomedine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "DEKK-TEC, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 29,
      "start_date": "2013-09",
      "completion_date": "2020-08",
      "has_results": true,
      "last_update_posted_date": "2020-09-16",
      "last_synced_at": "2026-10-24T06:25:03.128Z",
      "location_count": 3,
      "location_summary": "New Orleans, Louisiana • Lansing, Michigan • Houston, Texas",
      "locations": [
        {
          "city": "New Orleans",
          "state": "Louisiana"
        },
        {
          "city": "Lansing",
          "state": "Michigan"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02038218"
    },
    {
      "nct_id": "NCT05500508",
      "title": "Oral AMXT 1501 Dicaprate in Combination With IV DFMO",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Cancer",
        "Solid Tumor",
        "Solid Carcinoma",
        "Advanced Cancer",
        "DIPG Brain Tumor",
        "Ovary Cancer",
        "Breast Cancer",
        "Papillary Thyroid Cancer",
        "Head and Neck Cancer",
        "Gastric Cancer",
        "Nsclc",
        "Mesotheliomas Pleural",
        "Mesothelioma Peritoneum",
        "Esophageal Cancer",
        "Diffuse Midline Glioma, H3 K27M-Mutant",
        "Endometrial Cancer",
        "Cervical Cancer",
        "Melanoma",
        "Colorectal Cancer",
        "Glioma, Malignant"
      ],
      "interventions": [
        {
          "name": "AMXT1501",
          "type": "DRUG"
        },
        {
          "name": "DFMO",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Aminex Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2022-11-29",
      "completion_date": "2024-12-12",
      "has_results": false,
      "last_update_posted_date": "2024-12-24",
      "last_synced_at": "2026-10-24T06:25:03.128Z",
      "location_count": 6,
      "location_summary": "Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota + 3 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05500508"
    }
  ]
}